BioCentury | Feb 20, 2012
Company News

BioDiem, Changchun BCHT deal

BioDiem granted Changchun exclusive rights to its live attenuated influenza virus (LIAV) technology for an egg-based production method for pandemic and seasonal influenza vaccines for the private market in China. BioDiem's LAIV technology delivers a...
BioCentury | Aug 8, 2011
Company News

BioDiem, Merck deal

BioDiem regained from Merck's Nobilon International B.V. unit worldwide rights, excluding Russia and the Commonwealth of Independent States (CIS), to BioDiem's live attenuated influenza vaccine (LAIV) technology. BioDiem said Merck returned rights as a result...
BioCentury | Oct 18, 2010
Company News

BioDiem, Merck infectious news

Merck informed BioDiem that due to ongoing restructuring efforts following its merger with Schering-Plough Corp. , Merck would be closing its Boxmeer, the Netherlands, facility belonging to the pharma's Nobilon International B.V. unit. The facility is...
BioCentury | Sep 27, 2010
Financial News

BioDiem completes private placement of common stock and warrants

BioDiem Ltd. (ASX:BDM), Melbourne, Australia Business: Infectious, Ophthalmic Date completed: 9/21/10 Type: Private placement of common stock and warrants Raised: A$1 million (US$946,000) Shares: 5.6 million Price: A$0.18 Shares after offering: 102 million Note: Investors...
BioCentury | Sep 20, 2010
Clinical News

BDM-E regulatory update

FDA granted Orphan Drug designation to BioDiem's BDM-E to treat retinitis pigmentosa. The synthetic peptide is in preclinical testing for the indication. The company is seeking partners and funding to start Phase I testing. BioDiem...
BioCentury | Jul 19, 2010
Company News

BioDiem, Serum Institute of India sales and marketing update

Serum Institute launched BioDiem's NasoVac live attenuated influenza vaccine (LAIV) against swine influenza A (H1N1) in India. Serum Institute has a sublicense to the vaccine under the World Health Organization's Pandemic Flu program. Nobilon International...
BioCentury | Jul 5, 2010
Financial News

BioDiem completes rights offering

BioDiem Ltd. (ASX:BDM), Melbourne, Australia Business: Infectious, Ophthalmic Date completed: 6/25/10 Type: Rights offering Raised: A$3.5 million (US$3.1 million) Shares: 19.5 million Price: A$0.18 Shares after offering: 94.4 million Investors: Existing investors Note: Shareholders were...
BioCentury | Apr 5, 2010
Financial News

BioDiem proposes rights offering

BioDiem Ltd. (ASX:BDM), Melbourne, Australia Business: Infectious Date announced: 3/25/10 Type: Rights offering To be raised: Up to A$7.5 million ($6.9 million) Shares: 41.9 million Price: A$0.18 Shares outstanding prior: 76.9 million Investors: Existing investors...
BioCentury | Jan 4, 2010
Company News

BioDiem, Merck sales and marketing update

BioDiem regained from Merck's Nobilon International B.V. unit full Japanese rights to market BioDiem's live attenuated influenza vaccine (LAIV) technology. The companies previously shared marketing rights to the technology in Japan under a 2004 deal....
BioCentury | Oct 19, 2009
Clinical News

SCH 900795: Phase Ib started

Schering-Plough began a double-blind, placebo-controlled, Belgian Phase Ib trial to evaluate intranasal SCH 900795 in 140 healthy adults ages 50 and up. BioDiem granted rights for its LAIV technology to Schering-Plough's Nobilon International B.V. subsidiary...
Items per page:
1 - 10 of 26